GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (LTS:0Y71) » Definitions » Short Interest

Malin (LTS:0Y71) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Malin Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Malin's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Malin's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's Short Interest distribution charts can be found below:

* The bar in red indicates where Malin's Short Interest falls into.


Malin Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (LTS:0Y71) » Definitions » Short Interest
Comparable Companies
ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692 SZSE:000538 BOM:500087 ITCI VTRS TSE:4507 NBIX NSE:TORNTPHARM SHSE:688506 BOM:543904 BOM:500124
Traded in Other Exchanges
MLC:Ireland
Address
50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Website
http://www.malinplc.com
Malin Corporation PLC is a global life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where they believe innovative life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines